OKYO Pharma Announces First Patients Enrolled In Phase 3 NEPTUNE Trial Of Urcosimod For Neuropathic Corneal Pain

OKYO Pharma Limited has enrolled the first patients in its Phase 3 NEPTUNE trial for urcosimod, aimed at treating neuropathic corneal pain (NCP), a condition with no FDA-approved treatments. The enrollment was conducted by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN. This trial represents a significant step for OKYO in addressing a major unmet medical need in ocular health.